Chemotherapy for the Older Adult with Cancer

  • Supriya Mohile
  • Nail Nagovskiy
  • Lodovico Balducci

Cancer is a disease of aging; approximately 60% of all cancers and 70% of cancer mortality occur in persons aged 65 years and over. Aging is a highly individualized process, characterized by physiologic and psychosocial changes that can affect tolerance to treatment. Older patients are a highly heterogeneous group, with varying levels of risk for functional or physical decline and mortality. Historically, clinical trials have not reflected the general population of older cancer patients due to the low numbers of older patients included and the strict inclusion criteria for healthy, “fit” older adults [1]. Therefore, the majority of patients aged 65 years and older with cancer are treated based on data derived from clinical trials that often describe the effects of treatment on the median-age population enrolled in the studies or on the elderly with good performance status.


Dose Reduction Febrile Neutropenia Subclinical Hypothyroidism Geriatric Assessment Vinca Alkaloid 


  1. 1.
    Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061–7.PubMedGoogle Scholar
  2. 2.
    Crome P, Flanagan RJ. Pharmacokinetic studies in elderly people. Are they necessary? Clin Pharmacokinet 1994;26:243–7.PubMedGoogle Scholar
  3. 3.
    Hurria A, Lichtman SM. Pharmacokinetics of chemotherapy in the older patient. Cancer Control 2007;14:32–43.PubMedGoogle Scholar
  4. 4.
    Holmes CE, Muss HB. Diagnosis and treatment of breast cancer in the elderly. CA Cancer J Clin 2003;53:227–44.PubMedGoogle Scholar
  5. 5.
    Giovanazzi-Bannon S, Rademaker A, Lai G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois Cancer Center study. J Clin Oncol 1994;12:2447–52.PubMedGoogle Scholar
  6. 6.
    Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Supp Oncol 2003;1:18–24.Google Scholar
  7. 7.
    Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582–7.PubMedGoogle Scholar
  8. 8.
    Rockwood K, Stadnyk K, MacKnight C, et al. A brief clinical instrument to classify frailty in elderly people. Lancet 1999;353:205–6.PubMedGoogle Scholar
  9. 9.
    Reuben DB, Rubenstein LV, Hirsch SH, et al. Value of functional status as a predictor of mortality: Results of a prospective study. Am J Med 1992;93:663–9.PubMedGoogle Scholar
  10. 10.
    Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824–31.PubMedGoogle Scholar
  11. 11.
    Hurria A, Lichtman SM, Gardes J, et al. Identifying vulnerable older adults with cancer: Integrating geriatric assessment into oncology practice. J Am Geriatr Soc 2007;55:1604–8.PubMedGoogle Scholar
  12. 12.
    Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol 2007;25:1936–44.PubMedGoogle Scholar
  13. 13.
    Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 2002;20:494–502.PubMedGoogle Scholar
  14. 14.
    Lichtman SM. Pharmacokinetics and pharmacodynamics in the elderly. Clin Adv Hematol Oncol 2007;5:181–2.PubMedGoogle Scholar
  15. 15.
    Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med 1990;6:257–67.PubMedGoogle Scholar
  16. 16.
    Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997;13:169–83.PubMedGoogle Scholar
  17. 17.
    Moore S. Facilitating oral chemotherapy treatment and compliance through patient/family-focused education. Cancer Nurs 2007;30:112–22; quiz 123–4.PubMedGoogle Scholar
  18. 18.
    Vestal RE. Aging and pharmacology. Cancer 1997;80:1302–10.PubMedGoogle Scholar
  19. 19.
    Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 2008;47:297–321.PubMedGoogle Scholar
  20. 20.
    Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet 2003;42:779–91.PubMedGoogle Scholar
  21. 21.
    Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61:331–9.PubMedGoogle Scholar
  22. 22.
    Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414–23.PubMedGoogle Scholar
  23. 23.
    Benedetti MS, Whomsley R, Canning M. Drug metabolism in the paediatric population and in the elderly. Drug Discov Today 2007;12:599–610.PubMedGoogle Scholar
  24. 24.
    Wildiers H, Highley MS, de Bruijn EA, et al. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42:1213–42.PubMedGoogle Scholar
  25. 25.
    Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278–85.PubMedGoogle Scholar
  26. 26.
    Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older adults. Br J Cancer 2008;98:517–22.PubMedGoogle Scholar
  27. 27.
    Artz AS, Fergusson D, Drinka PJ, et al. Prevalence of anemia in skilled-nursing home residents. Arch Gerontol Geriatr 2004;39:201–6.PubMedGoogle Scholar
  28. 28.
    Laurie SA, Jeyabalan N, Nicholas G, et al. Association between anemia arising during therapy and outcomes of chemoradiation for limited small-cell lung cancer. J Thorac Oncol 2006;1:146–51.PubMedGoogle Scholar
  29. 29.
    MacRae R, Shyr Y, Johnson D, et al. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 2002;64:37–40.PubMedGoogle Scholar
  30. 30.
    Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528–36.PubMedGoogle Scholar
  31. 31.
    Rudat V, Dietz A, Schramm O, et al. Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 1999;53:119–25.PubMedGoogle Scholar
  32. 32.
    Smith RE, Jr., Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040–50.PubMedGoogle Scholar
  33. 33.
    Kader AS, Lim JT, Berthelet E, et al. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. Am J Clin Oncol 2007;30:492–7.PubMedGoogle Scholar
  34. 34.
    Balducci L, Cohen HJ, Engstrom PF, et al. Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005;3:572–90.PubMedGoogle Scholar
  35. 35.
    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. Cancer 2004;100:228–37.PubMedGoogle Scholar
  36. 36.
    Crawford J, Althaus B, Armitage J, et al. Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5:188–202.PubMedGoogle Scholar
  37. 37.
    Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 2007;25:3158–67.PubMedGoogle Scholar
  38. 38.
    Balducci L. The geriatric cancer patient: Equal benefit from equal treatment. Cancer Control 2001;8:1–25; quiz 27–8.PubMedGoogle Scholar
  39. 39.
    Gussekloo J, van Exel E, de Craen AJ, et al. Thyroid status, disability and cognitive function, and survival in old age. J Am Med Assoc 2004;292:2591–9.Google Scholar
  40. 40.
    Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004;140:128–41.PubMedGoogle Scholar
  41. 41.
    Mariotti S. Thyroid function and aging: Do serum 3,5,3'-triiodothyronine and thyroid-stimulating hormone concentrations give the Janus response? J Clin Endocrinol Metab 2005;90:6735–7.PubMedGoogle Scholar
  42. 42.
    Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. J Am Med Assoc 2004;291:228–38.Google Scholar
  43. 43.
    Rockwood K, Tan M, Phillips S, et al. Prevalence of diabetes mellitus in elderly people in Canada: Report from the Canadian Study of Health and Aging. Age Ageing 1998;27:573–7.PubMedGoogle Scholar
  44. 44.
    Wilson PW, Kannel WB. Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol 2002;11:119–23, 125.Google Scholar
  45. 45.
    Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003;21:433–40.PubMedGoogle Scholar
  46. 46.
    Caudle AS, Kim HJ, Tepper JE, et al. Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer. Ann Surg Oncol 2008;15(7):1931–6.Google Scholar
  47. 47.
    Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab 2003;284:E7–12.PubMedGoogle Scholar
  48. 48.
    Larsson A, Skoog I, Aevarsson, et al. Regional cerebral blood flow in normal individuals aged 40, 75 and 88 years studied by 99Tc(m)-d, l-HMPAO SPET. Nucl Med Commun 2001;22:741–6.PubMedGoogle Scholar
  49. 49.
    Meier-Ruge W, Ulrich J, Bruhlmann M, et al. Age-related white matter atrophy in the human brain. Ann N Y Acad Sci 1992;673:260–9.PubMedGoogle Scholar
  50. 50.
    Shilling V, Jenkins V, Morris R, et al. The effects of adjuvant chemotherapy on cognition in women with breast cancer—Preliminary results of an observational longitudinal study. Breast 2005;14:142–50.PubMedGoogle Scholar
  51. 51.
    Vardy J, Wefel JS, Ahles T, et al. Cancer and cancer-therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop. Ann Oncol 2008;19:623–9.PubMedGoogle Scholar
  52. 52.
    Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003;21:4175–83.PubMedGoogle Scholar
  53. 53.
    Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006;71:1–9.PubMedGoogle Scholar
  54. 54.
    Korner H, Soreide K, Stokkeland PJ, et al. Systematic follow-up after curative surgery for colorectal cancer in Norway: A population-based audit of effectiveness, costs, and compliance. J Gastrointest Surg 2005;9:320–8.PubMedGoogle Scholar
  55. 55.
    Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26:549–55.PubMedGoogle Scholar
  56. 56.
    Flood KL, Carroll MB, Le CV, et al. Geriatric syndromes in elderly patients admitted to an oncology-acute care for elders unit. J Clin Oncol 2006;24:2298–303.PubMedGoogle Scholar
  57. 57.
    Naeim A, Reuben D. Geriatric syndromes and assessment in older cancer patients. Oncology (Williston Park) 2001;15:1567–77, 1580; discussion 1581, 1586, 1591.Google Scholar
  58. 58.
    Melcangi RC, Azcoitia I, Ballabio M, et al. Neuroactive steroids influence peripheral myelination: A promising opportunity for preventing or treating age-dependent dysfunctions of peripheral nerves. Prog Neurobiol 2003;71:57–66.PubMedGoogle Scholar
  59. 59.
    Malik B, Stillman M. Chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2008;8:56–65.PubMedGoogle Scholar
  60. 60.
    Bhagra A, Rao RD. Chemotherapy-induced neuropathy. Curr Oncol Rep 2007;9:290–9.PubMedGoogle Scholar
  61. 61.
    Solana R, Pawelec G, Tarazona R. Aging and innate immunity. Immunity 2006;24:491–4.PubMedGoogle Scholar
  62. 62.
    Straub RH, Cutolo M, Zietz B, et al. The process of aging changes the interplay of the immune, endocrine and nervous systems. Mech Ageing Dev 2001;122:1591–611.PubMedGoogle Scholar
  63. 63.
    Castle SC, Uyemura K, Fulop T, et al. A need to study the immune status of frail older adults. Immun Ageing 2006;3:1.PubMedGoogle Scholar
  64. 64.
    Minisini A, Spazzapan S, Crivellari D, et al. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors. Crit Rev Oncol Hematol 2005;53:125–31.PubMedGoogle Scholar
  65. 65.
    Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258–66.PubMedGoogle Scholar
  66. 66.
    Steensma DP, Tefferi A. Anemia in the elderly: How should we define it, when does it matter, and what can be done? Mayo Clin Proc 2007;82:958–66.PubMedGoogle Scholar
  67. 67.
    Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood 2004;104:2263–8.PubMedGoogle Scholar
  68. 68.
    Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003;21:366–73.PubMedGoogle Scholar
  69. 69.
    Heuser M, Ganser A, Bokemeyer C. Use of colony-stimulating factors for chemotherapy-associated neutropenia: Review of current guidelines. Semin Hematol 2007;44:148–56.PubMedGoogle Scholar
  70. 70.
    Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007;12:1416–24.PubMedGoogle Scholar
  71. 71.
    De Martinis M, Franceschi C, Monti D, et al. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 2006;80:219–27.PubMedGoogle Scholar
  72. 72.
    Walston J, McBurnie MA, Newman A, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: Results from the Cardiovascular Health Study. Arch Intern Med 2002;162:2333–41.PubMedGoogle Scholar
  73. 73.
    Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–56.PubMedGoogle Scholar
  74. 74.
    WHO. International Classification of Functioning, Disability and Health (ICF). World Health Organization. 2006.Google Scholar
  75. 75.
    Balducci L. Aging, frailty, and chemotherapy. Cancer Control 2007;14:7–12.PubMedGoogle Scholar
  76. 76.
    Monfardini S, Basso U. Oncological causes of frailty in older cancer patients. Eur J Cancer 2007;43:1230–1.PubMedGoogle Scholar
  77. 77.
    Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol 2006;60:144–51.PubMedGoogle Scholar
  78. 78.
    McEniery CM, Wilkinson IB, Avolio AP. Age, hypertension and arterial function. Clin Exp Pharmacol Physiol 2007;34:665–71.PubMedGoogle Scholar
  79. 79.
    Thomas S, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Clin Geriatr Med 2007;23:1–10.PubMedGoogle Scholar
  80. 80.
    Mangoni AA. Cardiovascular drug therapy in elderly patients: Specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations. Drugs Aging 2005;22:913–41.PubMedGoogle Scholar
  81. 81.
    Longhi A, Ferrari S, Bacci G, et al. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs 2007;18:737–44.PubMedGoogle Scholar
  82. 82.
    Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 2006;57:485–98.PubMedGoogle Scholar
  83. 83.
    Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 2004;109:3122–31.PubMedGoogle Scholar
  84. 84.
    Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001;19:2746–53.PubMedGoogle Scholar
  85. 85.
    Snowden JA, Hill GR, Hunt P, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000;26:309–13.PubMedGoogle Scholar
  86. 86.
    van Dalen EC, van der Pal HJ, Caron HN, et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2006;CD005008.Google Scholar
  87. 87.
    Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820–6.PubMedGoogle Scholar
  88. 88.
    Sprung J, Gajic O, Warner DO. Review article: Age related alterations in respiratory function—Anesthetic considerations [Article de synthèse: Les modifications de fonction respiratoire lieés a l'âge—Considerations anesthésiques]. Can J Anaesth 2006;53:1244–57.PubMedGoogle Scholar
  89. 89.
    Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: Impact on cancer management and decision making, part I. Cancer J 2005;11:449–60.PubMedGoogle Scholar
  90. 90.
    Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Sem Oncol 2006;33:98–105.Google Scholar
  91. 91.
    Connolly MJ, Crowley JJ, Charan NB, et al. Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax 1992;47:410–3.PubMedGoogle Scholar
  92. 92.
    Carmeli E, Coleman R, Reznick AZ. The biochemistry of aging muscle. Exp Gerontol 2002;37:477–89.PubMedGoogle Scholar
  93. 93.
    Baumgartner RN, Heymsfield SB, Lichtman S, et al. Body composition in elderly people: Effect of criterion estimates on predictive equations. Am J Clin Nutr 1991;53:1345–53.PubMedGoogle Scholar
  94. 94.
    Gallagher D, Ruts E, Visser M, et al. Weight stability masks sarcopenia in elderly men and women. Am J Physiol Endocrinol Metab 2000;279:E366–75.PubMedGoogle Scholar
  95. 95.
    Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147:755–63.PubMedGoogle Scholar
  96. 96.
    Hughes VA, Frontera WR, Dallal GE, et al. Muscle strength and body composition: Associations with bone density in older subjects. Med Sci Sports Exerc 1995;27:967–74.PubMedGoogle Scholar
  97. 97.
    Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: The Health ABC Study. J Gerontol A Biol Sci Med Sci 2002;57:M326–32.PubMedGoogle Scholar
  98. 98.
    Dreyer HC, Volpi E. Role of protein and amino acids in the pathophysiology and treatment of sarcopenia. J Am Coll Nutr 2005;24:140S–145S.Google Scholar
  99. 99.
    Szulc P, Duboeuf F, Marchand F, et al. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: The MINOS study. Am J Clin Nutr 2004;80:496–503.PubMedGoogle Scholar
  100. 100.
    Vandervoort AA. Aging of the human neuromuscular system. Muscle Nerve 2002;25:17–25.PubMedGoogle Scholar
  101. 101.
    Lindle RS, Metter EJ, Lynch NA, et al. Age and gender comparisons of muscle strength in 654 women and men aged 20–93 yr. J Appl Physiol 1997;83:1581–7.PubMedGoogle Scholar
  102. 102.
    Frontera WR, Hughes VA, Lutz KJ, et al. A cross-sectional study of muscle strength and mass in 45- to 78-yr-old men and women. J Appl Physiol 1991;71:644–50.PubMedGoogle Scholar
  103. 103.
    Wedding U, Kodding D, Pientka L, et al. Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol 2007;64:1–9.PubMedGoogle Scholar
  104. 104.
    Smith MR. Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol 2004;172:S52–6; discussion S56–7.PubMedGoogle Scholar
  105. 105.
    Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261–7.PubMedGoogle Scholar
  106. 106.
    Bylow K, Mohile SG, Stadler WM, et al. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: A conceptual review. Cancer 2007;110:2604–13.PubMedGoogle Scholar
  107. 107.
    Mohile SG, Bylow K, Dale W, et al. A pilot study of the Vulnerable Elders Survey-13 compared with the Comprehensive Geriatric Assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 2007;109:802–10.PubMedGoogle Scholar
  108. 108.
    Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: What do we really know? Nat Clin Pract Urol 2008;5:24–34.PubMedGoogle Scholar
  109. 109.
    Orsini LS, Rousculp MD, Long SR, et al. Health care utilization and expenditures in the United States: A study of osteoporosis-related fractures. Osteoporos Int 2005;16:359–71.PubMedGoogle Scholar
  110. 110.
    Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 1999;353:878–82.PubMedGoogle Scholar
  111. 111.
    Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 2002;137:526–8.Google Scholar
  112. 112.
    Tham YL, Sexton K, Weiss HL, et al. The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause. J Supp Oncol 2006;4:295–8, 304.Google Scholar
  113. 113.
    McKean H, Looker S, Hartmann LC, et al. Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions. J Nutr Educ Behav 2008;40:144–8.PubMedGoogle Scholar
  114. 114.
    Cabanillas ME, Lu H, Fang S, et al. Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures. Leuk Lymphoma 2007;48:1514–21.PubMedGoogle Scholar
  115. 115.
    Salomaa-Rasanen A, Kosunen TU, Mattila J, et al. Age-dependent accuracy of Helicobacter pyloriantibody assays for adults, with special emphasis on atrophic gastritis. Clin Diagn Lab Immunol 2004;11:1185–8.PubMedGoogle Scholar
  116. 116.
    Kupfer RM, Heppell M, Haggith JW, et al. Gastric emptying and small-bowel transit rate in the elderly. J Am Geriatr Soc 1985;33:340–3.PubMedGoogle Scholar
  117. 117.
    Okayasu I, Hana K, Tsuruta T, et al. Significant increase of colonic mutated crypts correlates with age in sporadic cancer and diverticulosis cases, with higher frequency in the left- than right-side colorectum. Cancer Sci 2006;97:362–7.PubMedGoogle Scholar
  118. 118.
    Wegener M, Borsch G, Schaffstein J, et al. Effect of ageing on the gastro-intestinal transit of a lactulose-supplemented mixed solid-liquid meal in humans. Digestion 1988;39:40–6.PubMedGoogle Scholar
  119. 119.
    Salles N. Basic mechanisms of the aging gastrointestinal tract. Dig Dis 2007;25:112–7.PubMedGoogle Scholar
  120. 120.
    Nagler RM. Salivary glands and the aging process: Mechanistic aspects, health-status and medicinal-efficacy monitoring. Biogerontology 2004;5:223–33.PubMedGoogle Scholar
  121. 121.
    Shugars DC, Watkins CA, Cowen HJ. Salivary concentration of secretory leukocyte protease inhibitor, an antimicrobial protein, is decreased with advanced age. Gerontology 2001;47:246–53.PubMedGoogle Scholar
  122. 122.
    Balducci L, Extermann M. Management of cancer in the older person: A practical approach. Oncologist 2000;5:224–37.PubMedGoogle Scholar
  123. 123.
    Posner MR, Haddad RI. Novel agents for the treatment of mucositis. J Support Oncol 2007;5:33–9.PubMedGoogle Scholar
  124. 124.
    Wynne HA, Cope LH, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297–301.PubMedGoogle Scholar
  125. 125.
    Meier JM, Alavi A, Iruvuri S, et al. Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography. Sem Nucl Med 2007;37:154–72.Google Scholar
  126. 126.
    Rosenman RH, Shibata E. Effect of age upon hepatic synthesis of cholesterol in rat. Proc Soc Exp Biol Med 1952;81:296–8.PubMedGoogle Scholar
  127. 127.
    Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998;34:359–73.PubMedGoogle Scholar
  128. 128.
    McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004;56:163–84.PubMedGoogle Scholar
  129. 129.
    Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43:14–34.PubMedGoogle Scholar
  130. 130.
    Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652–9.PubMedGoogle Scholar
  131. 131.
    Ferder LF, Inserra F, Basso N. Effects of renin-angiotensin system blockade in the aging kidney. Exp Gerontol 2003;38:237–44.PubMedGoogle Scholar
  132. 132.
    Saito T. SIADH and other hyponatremic disorders: Diagnosis and therapeutic problems. Nippon Jinzo Gakkai Shi 1996;38:429–34.PubMedGoogle Scholar
  133. 133.
    Ferder LF, Inserra F, Basso N. Advances in our understanding of aging: Role of the renin-angiotensin system. Curr Opin Pharmacol 2002;2:189–94.PubMedGoogle Scholar
  134. 134.
    Saito T. Hyponatremia in elderly patients. Intern Med 2001;40:851.PubMedGoogle Scholar
  135. 135.
    Ishikawa SE, Saito T, Kaneko K, et al. Hyponatremia responsive to fludrocortisone acetate in elderly patients after head injury. Ann Intern Med 1987;106:187–91.PubMedGoogle Scholar
  136. 136.
    Lichtman SM, Buchholtz M, Marino J, et al. Use of cisplatin for elderly patients. Age Ageing 1992;21:202–4.PubMedGoogle Scholar
  137. 137.
    Esposito C, Plati A, Mazzullo T, et al. Renal function and functional reserve in healthy elderly individuals. J Nephrol 2007;20:617–25.PubMedGoogle Scholar
  138. 138.
    Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70.PubMedGoogle Scholar
  139. 139.
    Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004;15:291–5.PubMedGoogle Scholar
  140. 140.
    Poole SG, Dooley MJ, Rischin D. A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. Ann Oncol 2002;13:949–55.PubMedGoogle Scholar
  141. 141.
    Wright JG, Boddy AV, Highley M, et al. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001;84:452–9.PubMedGoogle Scholar
  142. 142.
    Verhave JC, Fesler P, Ribstein J, et al. Estimation of renal function in subjects with normal serum creatinine levels: Influence of age and body mass index. Am J Kidney Dis 2005;46:233–41.PubMedGoogle Scholar
  143. 143.
    Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–56.PubMedGoogle Scholar
  144. 144.
    Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995;87:573–80.PubMedGoogle Scholar
  145. 145.
    Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer 2007;110:1376–84.PubMedGoogle Scholar
  146. 146.
    Tchambaz L, Schlatter C, Jakob M, et al. Dose adaptation of antineoplastic drugs in patients with liver disease. Drug Saf 2006;29:509–22.PubMedGoogle Scholar
  147. 147.
    Launay-Vacher V, Chatelut E, Lichtman SM, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007;18:1314–21.PubMedGoogle Scholar
  148. 148.
    Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405–11.PubMedGoogle Scholar
  149. 149.
    Balducci L, Extermann M. Cancer chemotherapy in the older patient: What the medical oncologist needs to know. Cancer 1997;80:1317–22.PubMedGoogle Scholar
  150. 150.
    Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900–5.PubMedGoogle Scholar
  151. 151.
    Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869–79.PubMedGoogle Scholar
  152. 152.
    Platel D, Pouna P, Bonoron-Adele S, et al. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anticancer Drugs 1999;10:671–6.PubMedGoogle Scholar
  153. 153.
    Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of chemotherapy in older patients—An analysis of the medical literature. J Clin Oncol 2007;25:1832–43.PubMedGoogle Scholar
  154. 154.
    Wiseman LR, Spencer CM. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 1997;10:473–85.PubMedGoogle Scholar
  155. 155.
    Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521–9.PubMedGoogle Scholar
  156. 156.
    Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 2003;51:395–402.PubMedGoogle Scholar
  157. 157.
    Lorusso V, Manzione L, Silvestris N. Role of liposomal anthracyclines in breast cancer. Ann Oncol 2007;18(Suppl 6):vi70–3.PubMedGoogle Scholar
  158. 158.
    Yamamoto N, Tamura T, Maeda M, et al. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol 1995;36:102–6.PubMedGoogle Scholar
  159. 159.
    Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987;5:304–9.PubMedGoogle Scholar
  160. 160.
    Calvert AH, Egorin MJ. Carboplatin dosing formulae: Gender bias and the use of creatinine-based methodologies. Eur J Cancer 2002;38:11–6.PubMedGoogle Scholar
  161. 161.
    Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 2000;6:1205–18.PubMedGoogle Scholar
  162. 162.
    Takimoto CH, Graham MA, Lockwood G, et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 2007;13:4832–9.PubMedGoogle Scholar
  163. 163.
    Doroshow JH, Synold TW, Gandara D, et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Sem Oncol 2003;30:14–9.Google Scholar
  164. 164.
    Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085–91.PubMedGoogle Scholar
  165. 165.
    Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006;94:969–75.PubMedGoogle Scholar
  166. 166.
    Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: Final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005;104:282–9.PubMedGoogle Scholar
  167. 167.
    Montazeri A, Culine S, Laguerre B, et al. Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res 2002;8:394–9.Google Scholar
  168. 168.
    Montazeri A, Boucaud M, Lokiec F, et al. Population pharmacokinetics of topotecan: Intraindividual variability in total drug. Cancer Chemother Pharmacol 2000;46:375–81.PubMedGoogle Scholar
  169. 169.
    O'Reilly S, Armstrong DK, Grochow LB. Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan. Gynecol Oncol 1997;67:329–30.PubMedGoogle Scholar
  170. 170.
    O'Reilly S. Topotecan: What dose, what schedule, what route? Clin Cancer Res 1999;5:3–5.PubMedGoogle Scholar
  171. 171.
    Largillier R, Valenza B, Ferrero JM, et al. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. Oncology 2007;73:177–84.PubMedGoogle Scholar
  172. 172.
    Eckhardt SG. Irinotecan: A review of the initial phase I trials. Oncology (Williston Park) 1998;12:31–8.Google Scholar
  173. 173.
    Kawahara M. Irinotecan in the treatment of small cell lung cancer: A review of patient safety considerations. Expert Opin Drug Saf 2006;5:303–12.PubMedGoogle Scholar
  174. 174.
    Farhat FS. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 2007;24:137–46.PubMedGoogle Scholar
  175. 175.
    Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Sem Oncol 1998;25:39–46.Google Scholar
  176. 176.
    Mathijssen RH, Verweij J, Loos WJ, et al. Irinotecan pharmacokinetics-pharmacodynamics: The clinical relevance of prolonged exposure to SN-38. Br J Cancer 2002;87:144–50.PubMedGoogle Scholar
  177. 177.
    Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997;33:245–59.PubMedGoogle Scholar
  178. 178.
    Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182–94.PubMedGoogle Scholar
  179. 179.
    Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807–14.PubMedGoogle Scholar
  180. 180.
    Kim HG, Lee GW, Kang JH, et al. Combination chemotherapy with irinotecan and cisplatin in elderly patients (≥65 years) with extensive-disease small-cell lung cancer. Lung Cancer 2008;61(2):220–6.Google Scholar
  181. 181.
    Chau I, Norman AR, Cunningham D, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004;91:1453–8.PubMedGoogle Scholar
  182. 182.
    Kroschinsky FP, Friedrichsen K, Mueller J, et al. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. Cancer Chemother Pharmacol 2008;61:785–90.PubMedGoogle Scholar
  183. 183.
    Toffoli G, Corona G, Sorio R, et al. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol 2001;52:511–9.PubMedGoogle Scholar
  184. 184.
    Stewart CF. Use of etoposide in patients with organ dysfunction: Pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 1994;34(Suppl):S76–83.PubMedGoogle Scholar
  185. 185.
    Pfluger KH, Hahn M, Holz JB, et al. Pharmacokinetics of etoposide: Correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol 1993;31:350–6.PubMedGoogle Scholar
  186. 186.
    Ando M, Minami H, Ando Y, et al. Pharmacological analysis of etoposide in elderly patients with lung cancer. Clin Cancer Res 1999;5:1690–5.PubMedGoogle Scholar
  187. 187.
    Bressolle F, Bologna C, Kinowski JM, et al. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol 1997;24:1903–9.Google Scholar
  188. 188.
    Mita AC, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24:552–62.PubMedGoogle Scholar
  189. 189.
    Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000;18:2780–7.PubMedGoogle Scholar
  190. 190.
    Shepherd FA, Abratt RP, Anderson H, et al. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Sem Oncol 1997;24:S7-50-S7-55.Google Scholar
  191. 191.
    Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997;53:1005–37.PubMedGoogle Scholar
  192. 192.
    Lichtman SM, Etcubanas E, Budman DR, et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: A prospective dose adjustment study. Cancer Invest 2002;20:904–13.PubMedGoogle Scholar
  193. 193.
    Rubin EH, Andersen JW, Berg DT, et al. Risk factors for high-dose cytarabine neurotoxicity: An analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol 1992;10:948–53.PubMedGoogle Scholar
  194. 194.
    Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992;10:1171–5.PubMedGoogle Scholar
  195. 195.
    Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol 1998;16:3537–41.Google Scholar
  196. 196.
    Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002;20:3999–4005.PubMedGoogle Scholar
  197. 197.
    Bradley CJ, Given CW, Dahman B, et al. Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer. Arch Intern Med 2008;168:521–9.PubMedGoogle Scholar
  198. 198.
    Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: A population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002;20:3992–8.PubMedGoogle Scholar
  199. 199.
    Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002;49:225–34.PubMedGoogle Scholar
  200. 200.
    Cassidy J, Twelves C, Cameron D, et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999;44:453–60.PubMedGoogle Scholar
  201. 201.
    Camidge R, Reigner B, Cassidy J, et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 2005;23:4719–25.PubMedGoogle Scholar
  202. 202.
    Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19:4097–106.PubMedGoogle Scholar
  203. 203.
    Twelves C. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Oncology (Williston Park) 2002;16:23–6.Google Scholar
  204. 204.
    Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696–704.PubMedGoogle Scholar
  205. 205.
    Wright TL, Twelves CJ. Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: Biological synergy or an artefact of trial design? Eur J Cancer 2002;38:1957–60.PubMedGoogle Scholar
  206. 206.
    Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: An Oncopaz cooperative group study. J Clin Oncol 2005;23:3104–11.PubMedGoogle Scholar
  207. 207.
    Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187–96.PubMedGoogle Scholar
  208. 208.
    Goldberg HL, Vannice SB. Pneumonitis related to treatment with paclitaxel. J Clin Oncol 1995;13:534–5.Google Scholar
  209. 209.
    Lichtman SM, Hollis D, Miller AA, et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 2006;24:1846–51.PubMedGoogle Scholar
  210. 210.
    Ramalingam S, Perry MC, La Rocca RV, et al. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 2008;113(3):542–6.Google Scholar
  211. 211.
    Comella P, Gambardella A, Frasci G, et al. Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials. Crit Rev Oncol Hematol 2008;65:164–71.PubMedGoogle Scholar
  212. 212.
    ten Tije AJ, Smorenburg CH, Seynaeve C, et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 2004;40:352–7.Google Scholar
  213. 213.
    ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23:1070–7.PubMedGoogle Scholar
  214. 214.
    Minami H, Ohe Y, Niho S, et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: Why is toxicity increased in elderly patients? J Clin Oncol 2004;22:2901–8.PubMedGoogle Scholar
  215. 215.
    Hurria A, Fleming MT, Baker SD, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006;12:6100–5.PubMedGoogle Scholar
  216. 216.
    Slaviero KA, Clarke SJ, McLachlan AJ, et al. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004;57:44–53.PubMedGoogle Scholar
  217. 217.
    Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001;19:163–9.PubMedGoogle Scholar
  218. 218.
    Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99–114.PubMedGoogle Scholar
  219. 219.
    Sinibaldi VJ. Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. Clin Interv Aging 2007;2:555–60.PubMedGoogle Scholar
  220. 220.
    Hainsworth JD, Burris HA, 3rd, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19:3500–5.PubMedGoogle Scholar
  221. 221.
    Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996;59:32–40.PubMedGoogle Scholar
  222. 222.
    Sorio R, Robieux I, Galligioni E, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997;33:301–3.PubMedGoogle Scholar
  223. 223.
    Gauvin A, Pinguet F, Culine S, et al. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 2000;6:2690–5.PubMedGoogle Scholar
  224. 224.
    Ekhart C, Kerst JM, Rodenhuis S, et al. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. Cancer Chemother Pharmacol 2009 Jan;63(2):375–9.Google Scholar
  225. 225.
    Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991;20:194–208.PubMedGoogle Scholar
  226. 226.
    Gelman RS, Taylor SGt. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984;2:1404–13.PubMedGoogle Scholar
  227. 227.
    Kergueris MF, Milpied N, Moreau P, et al. Pharmacokinetics of high-dose melphalan in adults: Influence of renal function. Anticancer Res 1994;14:2379–82.PubMedGoogle Scholar
  228. 228.
    Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001;114:600–7.PubMedGoogle Scholar
  229. 229.
    Jantunen E, Kuittinen T, Penttila K, et al. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (≥65 years) myeloma patients: Comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006;37:917–22.PubMedGoogle Scholar
  230. 230.
    Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998;16:2352–8.PubMedGoogle Scholar
  231. 231.
    Lyman GH, Kuderer N, Agboola O, et al. Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 2003;10:487–99.PubMedGoogle Scholar
  232. 232.
    O'Shaughnessy JA. Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer. Clin Breast Cancer 2007;8(Suppl 1):S11–21.PubMedGoogle Scholar
  233. 233.
    Dang CT, Fornier MN, Hudis CA. Risk models for neutropenia in patients with breast cancer. Oncology (Williston Park) 2003;17:14–20.Google Scholar
  234. 234.
    Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B Experience. J Clin Oncol 2007;25:3699–704.PubMedGoogle Scholar
  235. 235.
    Howard RA, Gilbert ES, Chen BE, et al. Leukemia following breast cancer: An international population-based study of 376,825 women. Breast Cancer Res Treat 2007;105:359–68.PubMedGoogle Scholar
  236. 236.
    Hudis CA, Schmitz N. Dose-dense chemotherapy in breast cancer and lymphoma. Sem Oncol 2004;31:19–26.Google Scholar
  237. 237.
    Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007;25:292–300.PubMedGoogle Scholar
  238. 238.
    Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007;99:196–205.PubMedGoogle Scholar
  239. 239.
    Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: Understanding risk. J Clin Oncol 2007;25:3871–6.PubMedGoogle Scholar
  240. 240.
    Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258–70.PubMedGoogle Scholar
  241. 241.
    Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J Am Med Assoc 2008;299:914–24.Google Scholar
  242. 242.
    Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18:1412–22.PubMedGoogle Scholar
  243. 243.
    Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11–7.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Supriya Mohile
    • 1
  • Nail Nagovskiy
    • 1
  • Lodovico Balducci
    • 2
  1. 1.University of Rochester Medical CenterRochesterUSA
  2. 2.H. Lee Moffitt Cancer Center and Research InstituteTampaUSA

Personalised recommendations